SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Closed
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
DiscoverBSX
HealthcareNYSEUSD

Boston Scientific

$0012345678900123456789.0012345678900123456789-4.9%
52w low (est.) $36.19$55.72 52w high (est.)
Peers
Market data
Market cap
$66.54B
52-week range
$42.20 – $109.50
Beta (vs market)
0.58
Sector
Healthcare
Valuation
P/E ratio
18.7x
DCF fair value
$92.02
Margin of safety
+106.2%
Forward P/E
12.1x
PEG ratio
0.54
Quality & efficiency
Moat score
76/100
Return on equity
14.7%
Profit margin
17.3%
Debt / equity
0.42
Growth & analysts
Revenue growth (YoY)
+11.6%
Analyst target
$73.86
Target upside
+65.5%
Analysts covering
29

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Valuation

ValueGrowthProfitHealthIncome55QUALITY
Overall Rating
78
Strong Buy
Strong Buy
Moat Score76
DCF Intrinsic Value
$92.02+106.2% upside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$66.54B
P/E Ratio
18.7
Dividend Yield
0.00%
Revenue Growth
+11.6%
Profit Margin
17.3%
ROE
14.7%
Debt / Equity
0.42
Beta
0.58
Beaten Down
vs Healthcare sector:P/E 19 vs 28 · cheaperMoat 76 vs 7Yield 0.00% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · BSX